{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:51:06Z","timestamp":1787017866019,"version":"build-2736575974"},"reference-count":53,"publisher":"American Association for Cancer Research (AACR)","issue":"1","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Janus-activated kinase 2 (JAK2) mutations are common in myeloproliferative disorders; however, although they are detected in virtually all polycythemia vera patients, they are found in \u223c50% of essential thrombocythemia (ET) patients, suggesting that converging pathways\/abnormalities underlie the onset of ET. Recently, the chromosomal translocation 3;21, leading to the fusion gene AML1\/MDS1\/EVI1 (AME), was observed in an ET patient. After we forced the expression of AME in the bone marrow (BM) of C57BL\/6J mice, all the reconstituted mice died of a disease with symptoms similar to ET with a latency of 8 to 16 months. Peripheral blood smears consistently showed an elevated number of dysplastic platelets with anisocytosis, degranulation, and giant size. Although the AME-positive mice did not harbor Jak2 mutations, the BM of most of them had significantly higher levels of activated Stat3 than the controls. With combined biochemical and biological assays we found that AME binds to the Stat3 promoter leading to its up-regulation. Signal transducers and activators of transcription 3 (STAT3) analysis of a small group of ET patients shows that in about half of the patients, there is STAT3 hyperactivation independently of JAK2 mutations, suggesting that the hyperactivation of STAT3 by JAK2 mutations or promoter activation may be a critical step in development of ET. [Cancer Res 2009;69(1):262\u201371]<\/jats:p>","DOI":"10.1158\/0008-5472.can-08-2534","type":"journal-article","created":{"date-parts":[[2008,12,31]],"date-time":"2008-12-31T03:22:49Z","timestamp":1230693769000},"page":"262-271","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Consistent Up-regulation of Stat3 Independently of Jak2 Mutations in a New Murine Model of Essential Thrombocythemia"],"prefix":"10.1158","volume":"69","author":[{"given":"Vitalyi","family":"Senyuk","sequence":"first","affiliation":[{"name":"1Medicine and Departments of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciro Roberto","family":"Rinaldi","sequence":"additional","affiliation":[{"name":"1Medicine and Departments of"},{"name":"4Department of Biochemistry and Medical Biotechnology, University Federico II, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donglan","family":"Li","sequence":"additional","affiliation":[{"name":"1Medicine and Departments of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Cattaneo","sequence":"additional","affiliation":[{"name":"1Medicine and Departments of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Stojanovic","sequence":"additional","affiliation":[{"name":"2Pharmacology, University of Illinois at Chicago; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Pane","sequence":"additional","affiliation":[{"name":"4Department of Biochemistry and Medical Biotechnology, University Federico II, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Du","sequence":"additional","affiliation":[{"name":"2Pharmacology, University of Illinois at Chicago; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadim","family":"Mahmud","sequence":"additional","affiliation":[{"name":"1Medicine and Departments of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Dickstein","sequence":"additional","affiliation":[{"name":"3Department of Pathology, University of Chicago, Chicago, Illinois; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Nucifora","sequence":"additional","affiliation":[{"name":"1Medicine and Departments of"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2008,12,31]]},"reference":[{"key":"2022061700284294200_B1","doi-asserted-by":"crossref","unstructured":"Harris NL, Jaffe ES, Diebold J, et al. World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues: Report of the Clinical Advisory Committee Meeting - Airlie House, Virginia, November 1997. J Clin Oncol\u20081999; 17: 3835\u201349.","DOI":"10.1200\/JCO.1999.17.12.3835"},{"key":"2022061700284294200_B2","doi-asserted-by":"crossref","unstructured":"Tefferi A, Gilliland DG. Oncogenes in myeloproliferative disorders. Cell Cycle\u20082007; 6: 550\u201366.","DOI":"10.4161\/cc.6.5.3919"},{"key":"2022061700284294200_B3","doi-asserted-by":"crossref","unstructured":"Epstein E, Goedel A. Hammorhagische thrombocythamie bei vascularer schrumpfmilz. Virch Arch Pathol Anat\u20081934; 292: 233.","DOI":"10.1007\/BF01891529"},{"key":"2022061700284294200_B4","doi-asserted-by":"crossref","unstructured":"Gunz FW. Hemorrhagic thrombocythemia: a critical review. Blood\u20081960; 15: 706\u201323.","DOI":"10.1182\/blood.V15.5.706.706"},{"key":"2022061700284294200_B5","doi-asserted-by":"crossref","unstructured":"Ozer FL, Truax WE, Miesch DC, Levin WC. Primary hemorrhagic thrombocythemia. Am J Med\u20081960; 26: 807\u201323.","DOI":"10.1016\/0002-9343(60)90136-4"},{"key":"2022061700284294200_B6","doi-asserted-by":"crossref","unstructured":"Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet\u20082005; 365: 1054\u201361.","DOI":"10.1016\/S0140-6736(05)71142-9"},{"key":"2022061700284294200_B7","doi-asserted-by":"crossref","unstructured":"James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera. Nature\u20082005; 434: 1144\u201348.","DOI":"10.1038\/nature03546"},{"key":"2022061700284294200_B8","doi-asserted-by":"crossref","unstructured":"Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell\u20082005; 7: 387\u201397.","DOI":"10.1016\/j.ccr.2005.03.023"},{"key":"2022061700284294200_B9","doi-asserted-by":"crossref","unstructured":"Yin CC, Cortes J, Barkoh B, Hayes K, Kantarjian H, Jones D. t(3;21)(q26;q22) in myeloid leukemia. Cancer\u20082006; 106: 1730\u20138.","DOI":"10.1002\/cncr.21797"},{"key":"2022061700284294200_B10","doi-asserted-by":"crossref","unstructured":"Rubin CM, Larson RA, Bitter MA, et al. Association of a chromosomal 3;21 translocation with the blast phase of chronic myelogenous leukemia. Blood\u20081987; 70: 1338\u201342.","DOI":"10.1182\/blood.V70.5.1338.1338"},{"key":"2022061700284294200_B11","doi-asserted-by":"crossref","unstructured":"Nucifora G, Birn DJ, Espinosa R III, et al. Involvement of the AML1 gene in the t(3;21) in therapy-related leukemia and in chronic myeloid leukemia in blast crisis. Blood\u20081993; 81: 2728\u201334.","DOI":"10.1182\/blood.V81.4.883.bloodjournal814883"},{"key":"2022061700284294200_B12","doi-asserted-by":"crossref","unstructured":"Nucifora G, Begy KR, Kobayashi H, et al. Consistent intergenic splicing and production of multiple transcripts between AML1 at 21q22 and unrelated genes at 3q26 in (3;21)(q26;q22) translocations. Proc Natl Acad Sci U S A\u20081994; 91: 4004\u20138.","DOI":"10.1073\/pnas.91.9.4004"},{"key":"2022061700284294200_B13","doi-asserted-by":"crossref","unstructured":"Senyuk V, Chakraborty S, Mikhail FM, Zhao R, Chi Y, Nucifora G. The leukemia-associated transcription repressor AML1\/MDS1\/EVI1 requires CtBP to induce abnormal growth and differentiation of murine hematopoietic cells. Oncogene\u20082002; 21: 3232\u201340.","DOI":"10.1038\/sj.onc.1205436"},{"key":"2022061700284294200_B14","doi-asserted-by":"crossref","unstructured":"Lavau C, Luo RT, Du C, Thirman MJ. Retrovirus-mediated gene transfer of MLL-ELL transforms primary myeloid progenitors and causes acute myeloid leukemias in mice. Proc Natl Acad Sci U S A\u20082000; 97: 10984\u20139.","DOI":"10.1073\/pnas.190167297"},{"key":"2022061700284294200_B15","doi-asserted-by":"crossref","unstructured":"Forsberg EC, Serwold T, Kogan S, Weissman IL, Passegue\u0301 E. New evidence supporting megakaryocyte-erythrocyte potential of flk2\/flt3+ multipotent hematopoietic progenitors. Cell\u20082006; 126: 415\u201326.","DOI":"10.1016\/j.cell.2006.06.037"},{"key":"2022061700284294200_B16","doi-asserted-by":"crossref","unstructured":"Li Z, Zhang G, Le Breton GC, Gao X, Malik AB, Du X. Two waves of platelet secretion induced by thromboxane A2 receptor and a critical role for phosphoinositide 3-kinases. J Biol Chem\u20082003; 278: 30725\u201331.","DOI":"10.1074\/jbc.M301838200"},{"key":"2022061700284294200_B17","doi-asserted-by":"crossref","unstructured":"Senyuk V, Sinha KK, Li D, Rinaldi CR, Yanamandra S, Nucifora G. Repression of RUNX1 activity by EVI1: a new role of EVI1 in leukemogenesis. Cancer Res\u20082007; 67: 5658\u201366.","DOI":"10.1158\/0008-5472.CAN-06-3962"},{"key":"2022061700284294200_B18","doi-asserted-by":"crossref","unstructured":"Kouskouti A, Scheer E, Staub A, Tora L, Talianidis I. Gene-specific modulation of TAF10 function by SET9-mediated methylation. Mol Cell\u20082004; 14: 175\u201382.","DOI":"10.1016\/S1097-2765(04)00182-0"},{"key":"2022061700284294200_B19","unstructured":"Hawley RG, Lieu FH, Fong AZ, Hawley TS. Versatile retroviral vectors for potential use in gene therapy. Gene Ther\u20081994; 1: 136\u20138."},{"key":"2022061700284294200_B20","doi-asserted-by":"crossref","unstructured":"Thiele J, Kvasnicka HM, Schmitt-Graeff A. Acute panmyelosis with myelofibrosis. Leuk Lymph\u20082004; 45: 681\u20137.","DOI":"10.1080\/10428190310001625692"},{"key":"2022061700284294200_B21","doi-asserted-by":"crossref","unstructured":"Cashell AW, Buss DH. The frequency and significance of megakaryocytic emperipolesis in myeloproliferative and reactive states. Ann Hematol\u20081992; 64: 273\u20136.","DOI":"10.1007\/BF01695470"},{"key":"2022061700284294200_B22","doi-asserted-by":"crossref","unstructured":"Michiels JJ, Koudstaal PJ, Mulder AH, van Vliet HH. Transient neurologic and ocular manifestations in primary thrombocythemia. Neurology\u20081993; 43: 1107\u201310.","DOI":"10.1212\/WNL.43.6.1107"},{"key":"2022061700284294200_B23","doi-asserted-by":"crossref","unstructured":"Michiels JJ, Berneman Z, Van Bockstaele D, van der Planken M, De Raeve H, Schroyens W. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications. Semin Thromb Hemost\u20082006; 32: 174\u2013207.","DOI":"10.1055\/s-2006-939431"},{"key":"2022061700284294200_B24","doi-asserted-by":"crossref","unstructured":"Steensma DP, Tefferi A. Cytogenetic and molecular genetic aspects of essential thrombocythemia. Acta Haematol\u20082002; 108: 55\u201365.","DOI":"10.1159\/000064754"},{"key":"2022061700284294200_B25","doi-asserted-by":"crossref","unstructured":"Horikawa Y, Matsumura I, Hashimoto K, et al. Markedly reduced expression of platelet c-mpl receptor in essential thrombocythemia. Blood\u20081997; 90: 4031\u20138.","DOI":"10.1182\/blood.V90.10.4031"},{"key":"2022061700284294200_B26","doi-asserted-by":"crossref","unstructured":"Landolfi R, Cipriani MC, Novarese L. Thrombosis and bleeding in polycythemia vera and essential thrombocythemia: pathogenetic mechanisms and prevention. Best Practice Res Clin Haematol\u20082006; 19: 617\u201333.","DOI":"10.1016\/j.beha.2005.07.011"},{"key":"2022061700284294200_B27","doi-asserted-by":"crossref","unstructured":"Bermejo E, Alberto MF, Meschengieser SS, Lazzari MA. Assessment of platelet activation in myeloproliferative disorders with complementary techniques. Blood Coagul Fibrinolysis\u20082004; 15: 235\u201340.","DOI":"10.1097\/00001721-200404000-00006"},{"key":"2022061700284294200_B28","doi-asserted-by":"crossref","unstructured":"Cesar JM, de Miguel D, Garci\u0301a Avello A, Burgaleta C. Platelet dysfunction in primary thrombocythemia using the platelet function analyzer, PFA-100. Am J Clin Pathol\u20082005; 123: 772\u20137.","DOI":"10.1309\/K58EWK4HPD51U3BE"},{"key":"2022061700284294200_B29","unstructured":"Kobusiak-Prokopowicz M, Kuliczkowski W, Karolko B, Prajs I, Mazurek W. Platelet aggregation and P-selectin levels during exercise treadmill test in patients with ischaemic heart disease. Kardiol Pol\u20082006; 64: 1094\u2013100."},{"key":"2022061700284294200_B30","doi-asserted-by":"crossref","unstructured":"Petrides PE, Siegel F. Thrombotic complications in essential thrombocythemia (ET): clinical facts and biochemical riddles. Blood Cells Mol Dis\u20082006; 36: 379\u201384.","DOI":"10.1016\/j.bcmd.2005.12.031"},{"key":"2022061700284294200_B31","doi-asserted-by":"crossref","unstructured":"To\u0301th O, Calatzis A, Penz S, Losonczy H, Siess W. Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb Haemost\u20082006; 96: 781\u20138.","DOI":"10.1160\/TH06-05-0242"},{"key":"2022061700284294200_B32","doi-asserted-by":"crossref","unstructured":"Kiuchi N, Nakajima K, Ichiba M, et al. STAT3 is required for the gp130-mediated full activation of the c-myc gene. J Exp Med\u20081999; 189: 63\u201373.","DOI":"10.1084\/jem.189.1.63"},{"key":"2022061700284294200_B33","doi-asserted-by":"crossref","unstructured":"Shirogane T, Fukada T, Muller JM, Shima DT, Hibi M, Hirano T. Synergistic roles for Pim-1 and c-Myc in STAT3-mediated cell cycle progression and antiapoptosis. Immunity\u20081999; 11: 709\u201319.","DOI":"10.1016\/S1074-7613(00)80145-4"},{"key":"2022061700284294200_B34","doi-asserted-by":"crossref","unstructured":"Goerttler PS, Steimle C, Ma\u0308rz E, et al. The Jak2V617F mutation, PRV-1 overexpression, and EEC formation define a similar cohort of MPD patient. Blood\u20082005; 106: 2862\u20134.","DOI":"10.1182\/blood-2005-04-1515"},{"key":"2022061700284294200_B35","doi-asserted-by":"crossref","unstructured":"Bumm TG, Elsea C, Corbin AS, et al. Characterization of murine JAK2V617F-positive myeloproliferative disease. Cancer Res\u20082006; 66: 11156\u201365.","DOI":"10.1158\/0008-5472.CAN-06-2210"},{"key":"2022061700284294200_B36","doi-asserted-by":"crossref","unstructured":"Lacout C, Pisani DF, Tulliez M, Gachelin FM, Vainchenker W, Villeval JL. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood\u20082006; 108: 1652\u201360.","DOI":"10.1182\/blood-2006-02-002030"},{"key":"2022061700284294200_B37","doi-asserted-by":"crossref","unstructured":"Wernig G, Mercher T, Okabe R, Levine RL, Lee BH, Gilliland DG. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood\u20082006; 107: 4274\u201381.","DOI":"10.1182\/blood-2005-12-4824"},{"key":"2022061700284294200_B38","doi-asserted-by":"crossref","unstructured":"Tiedt R, Hao-Shen H, Sobas MA, Looser R, Dirnhofer S, Schwaller J, Skoda RC. Ratio of mutant JAK2\u2013617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood\u20082008; 111: 3931\u201340.","DOI":"10.1182\/blood-2007-08-107748"},{"key":"2022061700284294200_B39","doi-asserted-by":"crossref","unstructured":"Cuenco GM, Nucifora G, Ren R. Human AML1\/MDS1\/EVI1 fusion protein induces an acute myelogenous leukemia (AML) in mice: a model for human AML. Proc Natl Acad Sci U S A\u20082000; 97: 1760\u20135.","DOI":"10.1073\/pnas.030421197"},{"key":"2022061700284294200_B40","doi-asserted-by":"crossref","unstructured":"Zhang S, Ramsay ES, Mock BA. Cdkn2a, the cyclin-dependent kinase inhibitor encoding p16INK4a and p19ARF, is a candidate for the plasmacytoma susceptibility locus, Pctr1. Proc Natl Acad Sci U S A\u20081998; 95: 2429\u201334.","DOI":"10.1073\/pnas.95.5.2429"},{"key":"2022061700284294200_B41","doi-asserted-by":"crossref","unstructured":"Ertenli I, Kiraz S, Oztu\u0308rk MA, Haznedarog\u0306lu I, Celik I, Calgu\u0308neri M. Pathologic thrombopoiesis of rheumatoid arthritis. Rheumatol Int\u20082003; 23: 49\u201360.","DOI":"10.1007\/s00296-003-0289-0"},{"key":"2022061700284294200_B42","doi-asserted-by":"crossref","unstructured":"Jenkins BJ, Roberts AW, Greenhill CJ, et al. Pathologic consequences of STAT3 hyperactivation by IL-6 and IL-11 during hematopoiesis and lymphopoiesis. Blood\u20082007; 109: 2380\u20138.","DOI":"10.1182\/blood-2006-08-040352"},{"key":"2022061700284294200_B43","doi-asserted-by":"crossref","unstructured":"Chatti K, Farrar WL, Duhe\u0301 RJ. Tyrosine phosphorylation of the Janus kinase 2 activation loop is essential for a high-activity catalytic state but dispensable for a basal catalytic state. Biochemistry\u20082004; 43: 4272\u201383.","DOI":"10.1021\/bi036109b"},{"key":"2022061700284294200_B44","doi-asserted-by":"crossref","unstructured":"Reich NC, Liu L. Tracking STAT nuclear traffic. Nat Rev Immunol\u20082006; 6: 602\u201312.","DOI":"10.1038\/nri1885"},{"key":"2022061700284294200_B45","doi-asserted-by":"crossref","unstructured":"Yang J, Chatterjee-Kishore M, Staugaitis SM, et al. Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res\u20082005; 65: 939\u201347.","DOI":"10.1158\/0008-5472.939.65.3"},{"key":"2022061700284294200_B46","doi-asserted-by":"crossref","unstructured":"Teofili L, Martini M, Cenci T, et al. Different STAT-3 and STAT-5 phosphorylation discriminates among Ph-negative chronic myeloproliferative diseases and is independent of the V617F JAK-2 mutation. Blood\u20082007; 110: 354\u20139.","DOI":"10.1182\/blood-2007-01-069237"},{"key":"2022061700284294200_B47","doi-asserted-by":"crossref","unstructured":"Schwemmers S, Will B, Waller CF, et al. JAK2V617F-negative ET patients do not display constitutively active JAK\/STAT signaling. Exp Hematol\u20082007; 35: 1695\u2013703.","DOI":"10.1016\/j.exphem.2007.07.004"},{"key":"2022061700284294200_B48","doi-asserted-by":"crossref","unstructured":"Maki K, Yamagata T, Asai T, et al. Dysplastic definitive hematopoiesis in AML1\/EVI1 knock-in embryos. Blood\u20082005; 106: 2147\u201355.","DOI":"10.1182\/blood-2004-11-4330"},{"key":"2022061700284294200_B49","doi-asserted-by":"crossref","unstructured":"Elagib KE, Goldfarb AN. Regulation of RUNX1 transcriptional function by GATA-1. Crit Rev Eukaryot Gene Expr\u20082007; 17: 271\u201380.","DOI":"10.1615\/CritRevEukarGeneExpr.v17.i4.20"},{"key":"2022061700284294200_B50","doi-asserted-by":"crossref","unstructured":"Kostyak JC, Naik UP. Megakaryopoiesis: transcriptional insights into megakaryocyte maturation. Front Biosci\u20082007; 12: 2050\u201362.","DOI":"10.2741\/2210"},{"key":"2022061700284294200_B51","doi-asserted-by":"crossref","unstructured":"Kurokawa M, Mitani K, Imai Y, Ogawa S, Yazaki Y, Hirai H. The t(3;21) fusion product, AML1\/Evi-1, interacts with Smad3 and blocks transforming growth factor-\u03b2-mediated growth inhibition of myeloid cells. Blood\u20081998; 92: 4003\u201312.","DOI":"10.1182\/blood.V92.11.4003"},{"key":"2022061700284294200_B52","doi-asserted-by":"crossref","unstructured":"Sood R, Talwar-Trikha A, Chakrabarti SR, Nucifora G. MDS1\/EVI1 enhances TGF- \u03b21 signaling and strengthens its growth-inhibitory effect, but the leukemia-associated fusion protein AML1\/MDS1\/EVI1, product of the t(3;21), abrogates growth-inhibition in response to TGF- \u03b21. Leukemia\u20081999; 13: 348\u201357.","DOI":"10.1038\/sj.leu.2401360"},{"key":"2022061700284294200_B53","doi-asserted-by":"crossref","unstructured":"Kuroda H, Matsunaga T, Terui T, et al. Decrease of Smad4 gene expression in patients with essential thrombocythaemia may cause an escape from suppression of megakaryopoiesis by transforming growth factor-\u03b21. Br J Haematol\u20082004; 124: 211\u201320.","DOI":"10.1046\/j.1365-2141.2003.04755.x"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/69\/1\/262\/2609806\/262.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/69\/1\/262\/2609806\/262.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T04:28:07Z","timestamp":1684816087000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/69\/1\/262\/549541\/Consistent-Up-regulation-of-Stat3-Independently-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12,31]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2008,12,31]]},"published-print":{"date-parts":[[2009,1,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-08-2534","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,12,31]]}}}